Dear Editor,

Glucocorticoids are widely used to treat acute respiratory distress syndrome (ARDS) despite their use being highly controversial based on randomized controlled trials and meta-analyses \[[@CR1]\]. As type I interferons (IFNs) are our first line of defense against severe viral respiratory infections, we explored whether glucocorticoids interfere with IFN signaling and whether their use associates with outcome of IFN beta treatment of ARDS.

Methods are described in the eSupplement. We performed a propensity-matched post hoc analysis using data from the recent randomized INTEREST trial comparing IFN beta-1a to placebo in ARDS patients \[[@CR2]\]. Seventy-eight out of 144 patients (54%) included in the IFN beta-1a treatment arm of the INTEREST trial received glucocorticoids during the 28-day study period, 56% (44/78) at randomization (D0), 27% (21/78) during the treatment (D1--6) and 17% (13/78) after the treatment (D7 onward). Day-28 mortality for patients receiving glucocorticoids with IFN beta-1a was 39.7% compared to 10.6% for patients receiving IFN beta-1a alone. The Kaplan--Meier curves of the IFN beta-1a treatment arm adjusted by ARDS severity and divided according to the overlapping (D0--D6) use of glucocorticoids with IFN beta-1a treatment demonstrate significantly increased mortality by glucocorticoid use (*p* = 0.0002, see supplement).

In the post hoc propensity-matched analysis of the IFN beta-1a arm (*n* = 144), baseline systemic glucocorticoid treatment was independently associated with D28 mortality (OR 5.4, 95% CI 2.1--13.9, *p* \< 0.001) according to logistic regression. When the propensity-matched analysis was performed using an exact matching (a precision of 0.01 propensity units), there were 49 pairs of patients who received or did not receive glucocorticoids (*n* = 98). Among these patients, OR for increased mortality was 4.6 (95% CI 1.6--13.5) for those who had baseline systemic glucocorticoid treatment and 3.5 (95% CI 1--12) for those who initiated glucocorticoid treatment while receiving IFN beta-1a (Fig. [1](#Fig1){ref-type="fig"}a).Fig. 1Glucocorticoid use associates with mortality and blunts IFN beta-induced CD73 upregulation in lung vasculature and IFN beta-1a dependent signaling pathways in pulmonary endothelial cells. **a** (i) Independent factors associated with Day28 mortality in all IFN beta-1a-treated patients (*n* = 144) by logistic regression adjusted for propensity score and ARDS severity (odds ratios, OR with 95% confidence intervals, CI). (ii) Association of glucocorticoid treatment with D28 mortality in only propensity-matched IFN beta-1a-treated patients (*n* = 98) by logistic regression (OR with 95% CI) **b** Immunohistochemical staining of CD73 (brown) in lung tissue incubated in the presence of IFN beta with or without hydrocortisone (HC) for 1 and 4 days (D). D0 indicates baseline expression of CD73 in fresh lung tissue. **c** Quantification of CD73 positive vessels/mm^2^. The samples were incubated in the presence of two different IFN beta-1a formulations (FP-1201, circles *n* = 10 (day 1) and *n* = 11 (day 4); DS, triangles *n* = 8). Each data point marks an individual. The dotted line represents the placebo-induced level of CD73 expression. Statistical significance was analyzed using the Mann--Whitney test. **d** Immunofluorescence staining of IRF9 in primary human pulmonary endothelial cells after IFN beta treatment with or without HC showing marked inhibition of nuclear translocation of IRF9 by HC, the representative results of three independent experiments with the similar results. **e** Immunoblotting of the cytosolic and nuclear fractions of pulmonary endothelial cells after IFN beta-1a ± HC demonstrating both decreased IRF9 signal and its nuclear translocation. Specific IRF9 band is indicated by an arrow, a representative blot of five independent analyses with the comparable results. GAPDH and H3 (histone) are loading controls for the cytoplasmic and nuclear fractions, respectively. **f** qPCR results of two independent experiments demonstrating the decrease in IFN beta-1a-triggered mRNA synthesis of IRF9 and STAT1 by HC. Scale bars 100 μm

Based on the results of these analyses, we utilized human lung tissue and pulmonary endothelial cell cultures to investigate the effect of hydrocortisone on IFN nuclear signaling and the protein transcription of CD73, a molecule responsible for vascular integrity and leukocyte infiltration to sites of inflammation \[[@CR3]\].

When IFN beta-1a was applied to the lung organ cultures, CD73 expression was upregulated. However, in the presence of hydrocortisone, CD73 upregulation was inhibited (Fig. [1](#Fig1){ref-type="fig"}b, c). IFN beta-1a signaling via its receptor leads to the formation of a heterotrimeric transcription complex ISGF3 containing STAT1-STAT2 and IRF9, which then enters the nucleus and binds to the IFN beta responsive elements of several genes or assembly on DNA \[[@CR4]\]. In pulmonary endothelial cell cultures, IFN beta-1a induced the translocation of IRF9 into the nucleus, which was reduced by hydrocortisone treatment (Fig. [1](#Fig1){ref-type="fig"}d, e). In addition, hydrocortisone treatment decreased IRF9 and STAT1 mRNA synthesis when measured by qPCR (Fig. [1](#Fig1){ref-type="fig"}f), which was also seen at the protein level in Fig. [1](#Fig1){ref-type="fig"}d.

We conclude that glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. This provides the mechanistic basis for the harmful association of glucocorticoids in IFN beta-treated patients in the INTEREST trial. This study takes the earlier preclinical evidence that steroids block endogenous IFN signaling \[[@CR5]\] to the critical care setting. Our findings give mechanistic support to the ICM recommendation not to use glucocorticoids at the early stages of severe COVID-19 or viral-induced ARDS in general and highly recommends not to use systemic glucocorticoids together with type I interferons because of the harmful effects of this combination.
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